Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival

Tomoko Yoshioka, Ikuo Miura, Masaaki Kume, Naoto Takahashi, Masataka Okamoto, Ryo Ichinohasama, Tadashi Yoshino, Motoko Yamaguchi, Makoto Hirokawa, Ken Ichi Sawada, Shigeo Nakamura

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

De novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5-DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5+DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5+DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5+DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5+DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalGenes Chromosomes and Cancer
Volume42
Issue number2
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cytogenetics
Chromosome Aberrations
Survival
Mantle-Cell Lymphoma
Incidence
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma : Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. / Yoshioka, Tomoko; Miura, Ikuo; Kume, Masaaki; Takahashi, Naoto; Okamoto, Masataka; Ichinohasama, Ryo; Yoshino, Tadashi; Yamaguchi, Motoko; Hirokawa, Makoto; Sawada, Ken Ichi; Nakamura, Shigeo.

In: Genes Chromosomes and Cancer, Vol. 42, No. 2, 02.2005, p. 149-157.

Research output: Contribution to journalArticle

Yoshioka, Tomoko ; Miura, Ikuo ; Kume, Masaaki ; Takahashi, Naoto ; Okamoto, Masataka ; Ichinohasama, Ryo ; Yoshino, Tadashi ; Yamaguchi, Motoko ; Hirokawa, Makoto ; Sawada, Ken Ichi ; Nakamura, Shigeo. / Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma : Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. In: Genes Chromosomes and Cancer. 2005 ; Vol. 42, No. 2. pp. 149-157.
@article{0c83b523449f4e6fb7a669172c0ad0af,
title = "Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival",
abstract = "De novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5-DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5+DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5+DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5+DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5+DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.",
author = "Tomoko Yoshioka and Ikuo Miura and Masaaki Kume and Naoto Takahashi and Masataka Okamoto and Ryo Ichinohasama and Tadashi Yoshino and Motoko Yamaguchi and Makoto Hirokawa and Sawada, {Ken Ichi} and Shigeo Nakamura",
year = "2005",
month = "2",
doi = "10.1002/gcc.20127",
language = "English",
volume = "42",
pages = "149--157",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma

T2 - Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival

AU - Yoshioka, Tomoko

AU - Miura, Ikuo

AU - Kume, Masaaki

AU - Takahashi, Naoto

AU - Okamoto, Masataka

AU - Ichinohasama, Ryo

AU - Yoshino, Tadashi

AU - Yamaguchi, Motoko

AU - Hirokawa, Makoto

AU - Sawada, Ken Ichi

AU - Nakamura, Shigeo

PY - 2005/2

Y1 - 2005/2

N2 - De novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5-DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5+DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5+DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5+DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5+DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.

AB - De novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5-DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5+DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5+DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5+DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5+DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.

UR - http://www.scopus.com/inward/record.url?scp=19944426055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426055&partnerID=8YFLogxK

U2 - 10.1002/gcc.20127

DO - 10.1002/gcc.20127

M3 - Article

C2 - 15543600

AN - SCOPUS:19944426055

VL - 42

SP - 149

EP - 157

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 2

ER -